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Abstract 
Background & Objectives Postnatal depression correlates with postpartum weight 
retention, and dysregulated cortisol metabolism is evident in depressed individuals. 
Cortisol metabolism, BMI and metabolic phenotype are robustly associated but the 
role of cortisol metabolism in postnatal mental health and weight loss has never 
been examined. Design A longitudinal observation. Patients 49 healthy women with 
uncomplicated pregnancy. Measurements BMI and urinary steroid metabolites at 1 
week and 1, 3, 6 and 12 months postpartum. Validated urinary steroid metabolite 
ratios were measured to determine the activities of 11β-hydroxysteroid 
dehydrogenases (11β-HSD) that interconvert inactive cortisone and active cortisol 
and the 5α-reductases that clear cortisol to its inactive metabolites. Postnatal 
depression symptoms were measured at 1, 6 and 12 months. Results Low 5α-
reductase activity was associated with greater weight loss across the first year, 
independent of demographics, breastfeeding and depression. Postpartum BMI 
change was unrelated to postnatal depression at any time. Symptoms of postnatal 
depression were related to higher cortisol metabolite production at 12 months, 
independent of demographics and breastfeeding.  Conclusions. Greatest weight 
loss in the postpartum year was associated with lower conversion of cortisone to 
cortisol and lower conversion of cortisol to its metabolites, supporting previous work 
that demonstrates the facilitative role of lower 5α-reductase and 11β-HSD-1 in weight 
loss. Greater depression symptoms were associated with higher cortisol metabolite 
production rates. Whilst weight and mental health are both associated with 
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dysregulation of the HPA axis, there may be different pathways towards depressed 
and obese phenotypes in healthy postpartum samples.  
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Background 
Maternal postpartum weight trajectories are important factors in immediate and long-
term maternal physical and mental health. Two thirds of women retain weight after 
pregnancy1. The risk of depression and anxiety is significantly higher in women who 
retain two or more BMI units at 6 months postpartum2. Women who gain excess 
weight during pregnancy are 2.15 times as likely to be overweight and 4.49 times as 
likely to be obese two decades later3. Unsuccessful postpartum weight loss is a risk 
factor for long-term obesity1,4 and postnatal adiposity tends to have centralised 
distribution thus increasing risk of disease5. There is considerable variability of 
postpartum weight change (e.g. mean (±SD) of +1.1kg (±7.6kg) at 14 months 
postpartum6) with lower weight retention predicted by married status, lower 
gestational weight gain and longer breastfeeding6. Maternal depressed mood has 
also been associated with poorer postpartum weight loss trajectories2 and obesity is 
a risk factor for postnatal depression7.  
 
Dysregulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis is common in 
obesity and mental health disorders, indicating a possible mechanistic link8. Women 
with higher prenatal depression scores have been shown to have higher salivary 
cortisol9 and maternal distress in pregnancy is related to plasma cortisol levels10 . 
However, some studies show weak associations11-12. This may be because 
relationships between pregnancy distress and circulating cortisol may not 
necessarily be linear or may vary with gestation12. For example, in one study of 
severely obese pregnant women, both very high and very low maternally reported 
anxiety was related to low serum cortisol levels13. Furthermore, higher serum cortisol 
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levels in late pregnancy predicts greater postpartum weight retention in severely 
obese women13. However, serum cortisol level does not mediate between mental 
health and postpartum weight retention13. In obese individuals, circulatory cortisol 
concentrations are often normal or low14 due to enhanced excretion accompanied by 
increased metabolic clearance15. Therefore, investigation of the role of cortisol 
metabolism, rather than level, in postnatal mental health and weight loss/retention is 
warranted.  
 
Little is known about the metabolic underpinnings of postpartum weight change or 
postpartum mental health. Steroid hormone metabolism has been linked to insulin 
resistance, obesity and the metabolic syndrome16. Longitudinal changes in 
glucocorticoid metabolism are associated with the development of adverse metabolic 
phenotypes, with higher total glucocorticoid production linked to increased BMI and 
abnormal glucose tolerance17. Examination of the activity of the enzymes 11ß-
hydroxysteroid dehydrogenase type 1 (11ß-HSD-1, which converts inactive cortisone 
to cortisol), 11ß-hydroxysteroid dehydrogenase type 2 (11ß-HSD-2, which converts 
cortisol to inactive cortisone) and 5α-reductase (which converts cortisol to its 
tetrahydrometabolites) has established their role in the development and 
maintenance of metabolic disease17. 11ß-HSD-1 is highly expressed in adipose 
tissue from obese individuals and inhibition of 11ß-HSD-1 results in weight loss and 
improvements in glycaemic control18-21. 11ß-HSD-2 is expressed in the kidney and 
has a role in controlling blood pressure via its blocking of cortisol’s activation of the 
mineralocorticoid receptor. There is a positive relationship between 5α-reductase 
and markers of insulin resistance22.  
 
 6 
In addition to its role in metabolic disease, cortisol metabolism is implicated in a 
number of mental health problems, particularly depression, anxiety and psychosis23-
25. 5α-reductase inhibitors have been associated with symptoms of depression26 and 
depressed patients show lower 5α-reductase and 11ß-HSD-2 activity suggesting 
less clearance of cortisol24. Pharmacological treatment of depression for 4 weeks 
results in increases in 5α-reductase activity to levels comparable to a non-depressed 
control group24.  
 
Previously, we have described postpartum corticosteroid metabolism in this cohort of 
women27. 11β-HSD-1 and 11β-HSD-2 activity did not show significant changes with 
time. 5α-reductase activity was low in the immediate post-partum period, increased 
over the initial 3 months and then gradually stabilised, returning to levels comparable 
to a comparison female cohort who had not recently been pregnant.  However, there 
has been no longitudinal assessment of the relationship between weight change and 
steroid metabolism postpartum. Neither has the role of steroid metabolism in 
maternal postnatal depression been previously examined. Therefore, this exploratory 
study aimed to describe the maternal postpartum weight change trajectory and 
associated pattern of glucocorticoid metabolism in a sample of UK women across 
the first postnatal year; examine the concurrent relationships between maternal 
glucocorticoid metabolism and maternal symptoms of postnatal depression; and 
examine the relationships between weight change and maternal glucocorticoid 
metabolism in the postpartum year independent of confounds of breastfeeding, 
demographics and maternal depression. We hypothesised that greater weight loss 
would be associated with lower 11β-HSD-1 and 5α-reductase activity, increased 
11β-HSD-2 activity and with a reduced total F metabolite production rate. We 
 7 
hypothesised that higher depression scores would be associated with greater weight 
retention as well as lower 5α-reductase and 11β-HSD-2 activity. We also predicted 
that higher 11β-HSD-1 activity and total F metabolite production rate would be 
related to poorer mental health.      
 
Method 
Materials and Methods 
The protocol received ethical approval from Birmingham East, North and Solihull 
Research Ethics Committee, UK (ref. 10/H1206/67). All procedures contributing to 
this work comply with the ethical standards of the relevant national and institutional 
committees on human experimentation and with the Helsinki Declaration of 1975, as 
revised in 2008. Birmingham Women’s NHS Foundation Trust granted research and 
development approval (ref. 10/BWH/NO95). Women without complications during 
pregnancy/labour on low risk maternity units in Birmingham, UK were approached 
after labour and gave fully informed written consent. Mothers were visited at 1-week, 
1-month, 3-, 6- and 12-months post-partum to collect urine samples and were 
weighed wearing light indoor clothing without shoes at 1-week, 1-, 6- and 12-months. 
Maternal height was measured at 1-week postpartum using a stadiometer. Maternal 
weight and height were converted into BMI (kg/m2). 
 
During the 1-week home visit, mothers reported their pre-pregnancy weight, 
pregnancy medical history and provided demographic information. At each time 
point, mothers gave a single urine sample and reported whether they were still 
breastfeeding. Mothers completed the Edinburgh Postnatal Depression Scale28 
(EPDS), a widely used and well-validated screening tool for postnatal depression, at 
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1, 6, and 12 months postpartum. Higher scores indicate greater symptoms and 
scores of 13 or above indicate that participants are probably suffering from clinical 
depression.  
 
Urinary steroid metabolite analysis  
Spot urine samples were analysed; absolute corticosteroid concentrations were 
corrected per g of urinary creatinine to assess absolute production rates. Previous 
work has demonstrated that spot urine samples yield measures of corticosteroid 
activity that are very highly correlated with measures from 24 hour samples (r=.959) 
and thus spot urine samples accurately reflect daily corticosteroid activity29. Gas 
chromatography / mass spectroscopy (GC/MS) was used to analyse urinary 
corticosteroid metabolites as described elsewhere16,30. Solid-phase extraction was 
used to extract free and conjugated steroids. Steroids were enzymatically released 
from conjugation and then re-extracted. Methyloxime-trimethylsilyethers (MO-TMS) 
were formed by adding internal standard (stigmasterol) prior to derivitization. The 
final derivative was dissolved in cyclohexane and transferred to a GC/MS 
autosampler vial. An Agilent 5973 instrument in selected-ion-monitoring (SIM) mode 
was used to run the samples.  
The sum of total cortisol metabolites (THF (tetrahydrocortisol), THE 
(tetrahydrocortisone), 5-THF, -cortolone, cortisone (E), cortisol (F), -cortolone, -
cortol, -cortol) was used to measure cortisol secretion rate (total F metabolites). 
Here, the term total F metabolites means the total of measured metabolites, not the 
complete excretion of all metabolites. The ratio of tetrahydro-metabolites of cortisol 
(THF + 5THF) to those of cortisone (THE) was used to measure 11-HSD-1 
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activity. The ratio of urinary cortisol (F) to cortisone (E) accurately reflects renal 11-
HSD-2 activity (with higher F/E ratios indicating decreased 11-HSD-2 activity). The 
activity of 5-reductase was inferred from measuring the ratio of 5THF/THF. 
 
Participants 
59 mothers (mean age 29±5years, mean BMI @ 1 week postpartum 26.9±3.9kg/m2) 
of 36 male and 23 female infants, who had spontaneous normal vaginal deliveries 
without complications, provided informed written consent to participate and gave a 
series of spot urine samples in the postpartum year. None had any significant past 
medical history or were taking any regular medication. Mothers with gestational 
diabetes, preeclampsia or pregnancy induced hypertension were excluded. Infants 
born prior to 36-weeks gestation or who were small for gestational age were not 
eligible for participation. Two mothers were pregnant at the 12-month visit, so their 
data were removed from all analyses. Urine samples and sufficient data for 
calculation of BMI change was available for 49 of the women who gave consent to 
take part in the study.  
 
Statistical approach 
Statistical analysis was undertaken using IBM SPSS v22. Repeated Measures 
ANOVAs were used to examine changes across time in BMI, postnatal depression 
and cortisol metabolism. Observed power was reported. Posthoc pairwise 
comparisons identified the source of significant effects. Maternal BMI change scores 
(ΔBMI) at each stage were calculated. Positive ΔBMI implies reductions in BMI. For 
parsimony, total postpartum ΔBMI score was calculated from 1 week to 12-months 
postpartum and used in all analyses of relationships between weight change and 
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cortisol metabolism. Pearson’s correlation coefficients between demographics, 
breastfeeding duration, symptoms of depression and maternal steroid metabolism 
determined the necessity to control for these covariates in subsequent analyses. 
Post hoc power estimates were calculated. Bonferroni corrections were not applied 
given their unnecessarily stringent effects because we did not want to increase the 
risk of type II error in this relatively small sample, given the exploratory nature of the 
work. Postnatal depression symptoms at 1, 6 and 12 months and overall ΔBMI 
across the postnatal year were then correlated with glucocorticoid metabolism at 
each data collection point, using one-tailed partial correlation analyses controlling for 
maternal age, education, income, smoking, alcohol consumption and total 
breastfeeding duration. Additionally, analysis of ΔBMI glucocorticoid metabolism 
relationships were adjusted for depression.  
Results 
Table 1 illustrates the descriptive and demographic information of participants 
providing weight and urine measures at each time point. 
 
Table 1 about here 
The sample were affluent, well educated, relatively healthy weight, predominantly 
White British, with high initial breastfeeding rates and low levels of pregnancy 
smoking. 
 
BMI change across the postpartum year 
Table 2 about here.  
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Table 2 illustrates the pattern of BMI and BMI change from pre-pregnancy to 1 year 
postpartum. BMI increased during pregnancy (3.2kg/m2 gained from pre-pregnancy 
to 1 week postpartum). Women lost some of this weight across the postpartum year, 
with a mean BMI loss of 1.7kg/m2 from 1 week to 12 months. However, overall, 
women retained an average of 1.5kg/m2 at 12 months in comparison to their pre-
pregnancy weight.  
 
Repeated Measures ANOVA demonstrated that BMI reduced significantly across the 
postnatal year (Pillai’s Trace F(4,45)=28.99, p<.0001, observed power =1). Posthoc 
pairwise comparisons showed significant postnatal reductions in BMI at all time 
points except between 6 and 12 months. All postnatal BMI measures were 
significantly higher than pre-pregnancy BMI (p<.0001). Measures at one week were 
greater than BMI at any other time point (p<.0001). BMI at one month was greater 
than BMI at 6 and 12 months (p<.0001). BMI at 6 and 12 months were not 
significantly different (see Figure 1a).  
 
Maternal symptoms of postnatal depression across the postpartum year 
Repeated Measures ANOVA demonstrated that there was no significant change in 
postnatal depression symptoms across the postnatal year although there was a 
trend towards fewer symptoms with time (Pillai’s Trace F(2,47)=2.71, p<.077; 
observed power .51). Posthoc pairwise comparisons showed a significant decrease 
in postnatal depression symptoms between 1 month and 12 months only (p<.023) 
(see Figure 1b).  
 
Maternal glucocorticoid metabolism across the postpartum year 
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Table 3 illustrates the pattern of cortisol metabolism from pre-pregnancy to 1 year 
postpartum. Steroid metabolite analysis from some of these individuals have been 
reported elsewhere in the context of infant growth and development across the first 
year of life27. Presented in Table 3 are the urinary steroid metabolite ratios reflective 
of specific enzyme activities for mothers where detailed pre and post partum weight 
measurements are available. 
Repeated Measures ANOVAs demonstrated that there was no statistically significant 
change in 11ß-HSD-2 activity (F(4,22)=2, p=.13, observed power= .51) or Total F 
metabolites (F(4,22)= 1.6, p=.21, observed power =.41 ) across the year.  There was 
a significant increase in both 5α-reductase activity (F(4,22)= 44.5, p=.0001; observed 
power =1.0) and 11β-HSD-1 activity (F(4,22)= 7.1, p=.001; observed power =.98). 
Post hoc pairwise comparisons showed a significant difference between 5α-
reductase activity at 1 week and all other time points (p<.0001) and at 1 month and 
all other time points (p<.0001). Activity was higher at 3 months than at 1 week and 1 
month and lower than at 6 and 12 months (p<.05). There were no significant 
differences between 6 and 12-month 5α-reductase activity.  Differences in 11β-HSD-
1 were less profound but post hoc comparisons showed a significant difference in 
11β-HSD-1 activity between 1 week and 1 month, and between 1 week and 6 
months (p<.05). 11β-HSD-1 activity at 1 month was also lower than that at 3 and 6 
months (p<.05). 11β-HSD-1 at 3 months was lower than at 6 months (p<.05). Finally, 
11β-HSD-1 activity at 6 months was significantly higher than at 12 months (p<.05) 
(see Figure 1 c-f).  
 
Figure 1 about here  
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To examine which variables were required as covariates in subsequent analyses, 
one tailed Pearson’s correlation coefficients between demographics, breastfeeding, 
symptoms of depression, postpartum ΔBMI and cortisol metabolism were calculated 
(Table 4). 
Table 4 about here 
Table 4 demonstrates that postpartum ΔBMI showed no correlation with postnatal 
depression and few significant correlations with demographics. Women who smoked 
less during pregnancy had greater postpartum ΔBMI. Symptoms of postnatal 
depression were not correlated with demographics or breastfeeding duration. 
Postnatal depression symptoms at 12 months were associated with greater total F 
metabolites at 12 months. Maternal age, income, education, smoking and alcohol 
consumption during pregnancy showed significant relationships with a number of 
indices of cortisol metabolism across the first year, and with 5α-reductase activity in 
particular. Longer breastfeeding was associated with lower activity of 11βHSD-2 and 
5α-reductase at 1 month, and greater total F metabolites at 12 months. Before 
adjustment for covariates, women who showed greatest ΔBMI in the postpartum 
year had significantly lower 11β-HSD-1 activity at 12 months postpartum. Women 
with greater 11ß-HSD-2 activity at 1 week showed more weight loss in the 
postpartum year.  Lower 5α-reductase activity at all time points was associated with 
greater postpartum ΔBMI. Lower total F metabolites at 6 months were associated 
with greater weight loss. Post hoc power estimates for these correlation analyses 
suggest the sample was sufficient to detect meaningful relationships, i.e. where 
effect sizes were moderate (.3) to large (.5). At n=40, power to detect a correlation of 
.3 was .62; to detect a correlation of .5, power was .97. 
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To examine the relationships between symptoms of postnatal depression with 
cortisol metabolism, and BMI change with cortisol metabolism, a series of partial 
correlations coefficients were calculated controlling for covariates (Table 5). 
Correlations between BMI change and cortisol metabolism were additionally 
adjusted for symptoms of depression at 12 months.  
 
Adjusted Relationships between symptoms of postnatal depression and maternal 
glucocorticoid metabolism across the postpartum year 
  
After adjusting for demographics and breastfeeding, the pattern of relationships 
between symptoms of postnatal depression and concurrent cortisol metabolism 
remained the same: women with poorer mental health at 12 months had greater 
concurrent total cortisol secretion rates. There were no other relationships between 
measures of depression and cortisol metabolism at any other time points.  
Adjusted Relationships between ΔBMI and maternal glucocorticoid metabolism 
across the postpartum year 
11ß-HSD activity  
After adjusting for covariates, greater ΔBMI was associated with significantly lower 
11β-HSD-1 activity at 1 week and 12 months postpartum. Women with greater 11ß-
HSD-2 activity at 1 week showed more weight loss in the postpartum year.  
5α-reductase activity  
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Adjusting for covariates removed the significance of 5α-reductase activity at one 
week and one month, and reduced the relationship between 6-month 5α-reductase 
activity and ΔBMI to a trend. Lower 5α-reductase activity at 3 months and 1 year 
remained significantly associated with greater postpartum ΔBMI.  
Total F Metabolites 
After adjusting for covariates, there were no significant associations between total F 
metabolites and ΔBMI.  
Discussion 
This study described maternal postpartum weight change, mental health and cortisol 
metabolism in a sample of healthy UK women across the postnatal year. Women 
experienced a mean BMI loss of 1.7kg/m2 from 1 week to 12 months postpartum and 
retained +1.5kg/m2 at 12 months postpartum in comparison to their pre-pregnancy 
weight with notably large variability in postpartum weight change. Postnatal 
depression levels were as expected, showing slight decline across the year. Levels 
of 11ß-HSD-2 and Total F metabolites did not show significant change, but levels of 
11ß-HSD-1 and 5α-reductase significantly increased between 1 week and 6 months 
postpartum, consistent with our previous analyses of a larger sample of this cohort24. 
However, there were few relationships between weight change and depression, 
demographics or breastfeeding duration. Indices of cortisol metabolism showed 
significant relationships with postnatal depression symptoms and postpartum weight 
change, underlining the importance of disturbances in the HPA axis for the prediction 
of postnatal weight change and mental health. However, the relationship between 
weight change and cortisol metabolism was independent of any relationship with 
depression.  
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Over the post-partum year, we have identified changes in steroid hormone 
metabolism that are associated with maternal weight loss. Most notably, in line with 
our hypotheses, lower 11β-HSD-1 and 5α-reductase activity was associated with 
enhanced weight loss when adjusted for covariates including depression. The role of 
steroid hormone metabolism in the regulation of weight has been extensively studied 
in the context of simple obesity and type 2 diabetes31, but has not previously been 
examined in maternal post-partum weight.  
11β-HSD-1 generates active glucocorticoid, cortisol, in metabolic target tissues 
including adipose, liver and muscle32. Interestingly, all clinical studies that have used 
selective 11β-HSD-1 inhibitors have demonstrated reproducible weight loss18,19,21 
and in our cohort, lower activity (at one week and 12 months) was associated with 
enhanced weight loss, which may reflect decreased adipocyte differentiation and 
lipid accumulation as a consequence of decreased tissue specific cortisol 
availability33. Although 11βHSD-2 is not thought to be expressed at significant levels 
in adipose tissue, the global increase in activity that we observed may also 
contribute to decreased tissue glucocorticoid availability. Only 11ßHSD-2 activity at 1 
week was associated with greater weight loss in the postnatal year, suggesting that 
urinary measures of this enzyme are not key determinants of postnatal weight loss 
nor key correlates of postnatal depression in healthy participants. 
Lower 5α-reductase activity at 3 and 12 months postpartum was associated with 
increased weight loss. There are 2 isoforms of 5α-reductase (type 1 and type 2) that 
have differential tissue specific expression profiles and both contribute to steroid 
hormone metabolism.34 Cross-sectional studies have demonstrated the association 
between increased 5α-reductase activity and adverse metabolic phenotype16,17,35. 
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This extends to simple obesity, non-alcoholic fatty liver disease and the adverse 
metabolic phenotype associated with polycystic ovary syndrome. Weight loss is 
associated with a reduction of 5α-reductase activity22. 5α-reductase clears 
glucocorticoids to their inactive dihydro-metabolites (subsequently converted to 
tetrahydro-metabolites by the action of 3α-hydroxysteroid dehydrogenase) and 
therefore limiting glucocorticoid availability to bind and activate the glucocorticoid 
receptor. In addition, they have a role in activating androgens, converting 
testosterone to the more potent androgen dihydrotestosterone. Lowering activity has 
the potential to decrease androgen availability whilst simultaneously reducing 
glucocorticoid clearance, and both androgens and glucocorticoids regulate fat mass. 
What remains unclear is whether changes in 5α-reductase reflect cause or 
consequence of changes in postpartum BMI; the associations that we have 
described cannot infer causality. Rodent models with genetic deletion of 5α-
reductase type 1 have an adverse metabolic phenotype, largely confined to the liver 
without alteration in fat mass36. Clinical studies in patients have shown that non-
selective 5α-reductase inhibition (type 1 and 2), but not exclusive type 2 inhibition, is 
associated with systemic and hepatic insulin resistance and with hepatic lipid 
accumulation37. Taken together, it seems likely that the changes that we have 
observed in 5α-reductase activity reflect a compensatory response such that with 
weight gain, glucocorticoid availability to bind and activate its receptor is limited. This 
may occur in response to the increased adrenal glucocorticoid output that is seen 
with increased weight 38. As weight falls, adrenal glucocorticoid output falls and as a 
result there is no longer the need to repress local glucocorticoid availability and in 
parallel therefore, 5α-reductase activity decreases. Therefore, patients with the 
largest weight loss display greatest reduction in 5α-reductase activity. 
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Total glucocorticoid production was significantly correlated with depression 
symptoms at 12 months, but there were no relationships between postnatal 
depression at any other time point or any other measures of cortisol metabolism. 
However, 6% of the women in the sample had EPDS scores indicating probable 
major depression at 12 months and mean EPDS score was 5, comparable to other 
relatively mentally healthy UK postnatal samples39. Despite this, women with more 
depression symptoms at 12 months had greater total cortisol metabolite production, 
previously associated with greater BMI and abnormal glucose tolerance17. The 
causal nature and long term implications of this relationship is impossible to 
determine from our data, but are consistent with the suggestion that women with 
greater, and/or more persistent, symptoms of postnatal depression may be at greater 
risk for the development of metabolic disorders. 
The clinical implications of these findings are limited at this stage given the healthy 
nature of our sample. However, for women with a problematic postnatal weight loss 
trajectory, selective 11β-HSD-1 inhibitors could be investigated as an adjunct to diet 
and lifestyle intervention to aid weight loss. Furthermore, examination of total 
glucocorticoid production using spot urine samples has the potential to offer a more 
personalised approach to the evaluation of future metabolic and mental health risk.   
In general, our findings regarding links between maternal postnatal mental health, 
weight retention and cortisol metabolism in this healthy sample show similarities to 
the patterns found in severely obese women, when serum cortisol levels were 
measured13; mental health was related to cortisol level, cortisol level was related to 
postnatal weight retention but cortisol level did not mediate the relationship between 
weight and mental health. Together, these studies provide evidence to support that 
weight and mental health are both associated with dysregulation of glucocorticoid 
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secretion and metabolism, but that there may be different pathways to depression 
and obesity. There are other important contributors to/moderators of the 
development of each phenotype that were not examined in this study, such as early 
biological programming, gene expression or experience of stress. Further work is 
required to better understand these pathways and their contributors to both physical 
and psychological postpartum morbidity. 
There are a number of limitations of this study. This was a relatively healthy weight 
sample with low levels of depression and our conclusions cannot be extrapolated to 
obese or depressed populations. The absence of expected relationships, such as 
that between weight change and depression, may be a result of this limitation. 
Furthermore, the sample was predominantly White, well educated, affluent, with high 
levels of breastfeeding. There are likely to be important demographic patterns in the 
relationships between weight retention, depression and cortisol metabolism that this 
study could not capture. In addition, we did not collect data on stressors such as 
sleep deprivation, which may have an impact on both mental health and cortisol 
metabolism40. Finally, we did not correct for multiple testing to reduce the risk of a 
type II error in this small exploratory study, which naturally increases risk of a type I 
error. Therefore these findings, whilst important for future hypothesis generation, 
require replication.  
In summary, this study significantly expands our understanding of the relationships 
between cortisol metabolism, mental health and weight change postpartum.  Lower 
activity of 11β-HSD-1 and 5α-reductase was associated with greater postpartum 
weight loss in healthy women, independent of demographics and depression. More 
depressed women also demonstrated higher cortisol secretion rates, independent of 
demographics and breastfeeding, but depression was unrelated to BMI change. In 
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healthy samples, cortisol metabolism is related to both BMI and symptoms of 
depression, but weight and depressed mood have independent pathways that link 
them to HPA activity.  
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Table 1. Demographics (%), concurrent BMI measures and symptoms of depression 
(Mean, SD) at each time point for the whole sample (N=49; column 2) and for all 
mothers providing urine samples at each time point (columns 3-7).  
 Whole sample  
(n=49) 
1 week 
(n=40) 
1 month 
(n=46) 
3 
months 
(n=42) 
6 
months 
(n=45) 
12 
months 
(n=39) 
Maternal age 
(years)  
Mean (SD) 
30.8 (5.5) 31.4 
(5.0) 
30.9 
(5.6) 
30.9 
(5.4) 
31.0 
(5.3) 
30.9 
(5.6) 
Maternal 
concurrent 
BMI 
(kg/m
2
)  
Mean (SD) 
27.0 (3.7) @1 wk 
26.5 (3.6) @1 mo 
25.7 (3.8) @6 mo 
25.3 (3.7) @12 mo 
26.7 
(3.7) 
26.2 
(3.6) 
 
- 25.6 
(3.9) 
 
25.3 
(3.9) 
 
EPDS score 
Mean (SD) 
6.3 (4.6) @1 mo 
5.7 (4.5) @6 mo 
4.9 (4.4) @12 mo 
- 6.1 
(4.6) 
- 5.4 
(4.4) 
4.9 
(4.7) 
Percent (n) 
depressed 
(EPDS ≥13) 
8% (4) @1 mo 
4% (2) @6 mo 
6% (3) @12 mo 
- 8.7% 
(4) 
- 4.4% 
(2) 
7.7% 
(3) 
Percent  (n) 
some 
breastfeeding  
82% (40) @1 wk 
71% (35) @1 mo 
63% (31) @3 mo 
59% (29) @6 mo 
33% (16) @12 mo 
85% 
(34) 
70% 
(32) 
69% 
(29) 
62% 
(28) 
33% 
(13) 
Percent  (n) 
Infant gender 
55% (27) male 65% 
(26) 
male 
58.7%  
(27) 
male 
54.8% 
(23) 
male 
57.8% 
(26) 
male 
56.4% 
(22) 
male 
Percent  (n) 
Degree 
educated  
41% (20)  45% 
(18) 
43.5% 
(20) 
45% 
(19) 
42.2% 
(19) 
41% 
(16) 
Percent  (n) In 
highest 
65% (32) 77.5% 
(31) 
67.4% 
(31) 
69% 
(29) 
68.9% 
(31) 
66.7% 
(26) 
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income 
bracket 
Percent  (n) 
Smoked in 
pregnancy 
10% (5) 7.5% 
(3) 
6.5% 
(3) 
9.5% 
(4) 
8.9% 
(4) 
10% (4) 
Percent  (n) 
Consumed 
alcohol in 
pregnancy 
43% (21) 50% 
(20) 
43.5% 
(20) 
45.2% 
(19) 
44.4% 
(20) 
43.6% 
(17) 
Percent  (n) 
Primary ethnic 
groups 
57% (28) White 
British 
12% (6) White Other 
12% (6) Asian 
Pakistani 
57.5% 
(23) 
White 
British 
12.5% 
(5) White 
Other 
10% (4) 
Asian 
Pakistani 
58.7% 
(27) 
White 
British 
13% (6) 
White 
Other 
10.9% 
(5) Asian 
Pakistani 
54.8% 
(23) 
White 
British 
14.3% 
(6) White 
Other 
9.5% (4) 
Asian 
Pakistani 
57.8% 
(26) 
White 
British 
13.3% 
(6) White 
Other 
8.9% (4) 
Asian 
Pakistani 
61.5% 
(24) 
White 
British 
15.4% 
(6) White 
Other 
7.7% 
Asian 
Pakistani 
(3) 
7.7% (3) 
Black 
Caribbean 
N sizes for each time point vary because some mothers did not produce urine 
samples for all visits.  Percentages in columns 3-7 are expressed as a function of the 
number of women providing urine samples at each time point. 
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Table 2. BMI and ΔBMI from pre-pregnancy to 1 year postpartum (N=49). BMI 
expressed as (kg/m2)  
 Minimum Maximum Mean Std. 
Deviation 
Pre-pregnancy BMI 18.8 31.9 23.8 3.1 
1-week maternal BMI 19.2 35.7 27.0 3.7 
1 month maternal BMI 18.8 35.9 26.5 3.6 
6 month maternal BMI 19.5 35.2 25.7 3.8 
12 month maternal BMI 18.9 36.4 25.3 3.8 
ΔBMI pre-pregnancy to 1 
week postpartum 
-8.1 .7 -3.2 2.3 
ΔBMI 1 week postpartum to 1 
month postpartum 
-.4 3.3 .5 .7 
ΔBMI 1 month postpartum to 
6 months postpartum 
-2.5 4.7 .8 1.6 
ΔBMI 6 months postpartum to 
12 months postpartum  
-5.4 3.1 .4 1.5 
ΔBMI pre-pregnancy to 12 
months postpartum 
-7.6 3.0 -1.5 2.4 
ΔBMI 1 week postpartum to 
12 months postpartum 
-4.6 7.8 1.7 2.3 
ΔBMI = change in BMI (kg/m2). Positive ΔBMI is indicative of weight loss. 
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Table 3. Urinary steroid metabolite ratios as measured by gas chromatography / 
mass spectrometry across the first post-partum year. 
THF =tetrahydrocortisol, THE =tetrahydrocortisone, E=cortisone, F=cortisol 
Steroid ratio Time point N Min. Max. Mean SD 
THF+5THF/ THE 
 
(11β-HSD-1 activity;  
conversion of cortisone to 
cortisol) 
1-week 40 0.45 1.31 0.86 0.2 
1 month 46 0.48 1.21 0.83 0.18 
3 months 42 0.51 1.55 0.89 0.24 
6 months 45 0.56 1.47 0.99 0.21 
12 months 39 0.5 1.3 0.84 0.20 
F/E 
 
(11-βHSD-2 activity;  
conversion of cortisol to 
cortisone) 
1-week 40 0.39 1.69 0.8 0.26 
1 month  46 0.33 2.19 0.67 0.29 
3 months 42 0.36 1.39 0.65 0.23 
6 months  45 0.36 1.93 0.65 0.25 
12 months  39 0.29 1.33 0.63 0.24 
5THF/THF 
 
(5α-reductase activity ;  
clearance of cortisol to 
tetrahydrometabolites) 
1-week 40 0.08 0.46 0.2 0.09 
1 month 46 0.11 1.32 0.47 0.29 
3 months 42 0.24 2.32 0.85 0.43 
6 months 45 0.18 3.17 1.00 0.59 
12 months 39 0.35 2.5 0.99 0.43 
Total F Metabolites 
  
(μg/g urinary creatinine;  
total cortisol metabolite 
production) 
1-week 40 1123.0 17489.0 6346.6 4277.7 
1 month 46 728.0 19811.0 7784.9 5091.3 
3 months 42 1515.0 31204.0 7472.8 6496.3 
6 months 45 1023.0 27826.0 9849.1 8278.4 
12 months 39 1374.0 28322.0 8990.8 6942.1 
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Table 4. Unadjusted one tailed Pearson’s correlation coefficients between demographics, pregnancy 
smoking, pregnancy alcohol consumption, breastfeeding duration, with ΔBMI and cortisol metabolism.  
 T
im
e
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ΔBMI 
 
1 week-  
12 months 
- - .17 .18 -.01 -.32* .10 .03 
Depression 
(EPDS)  
 
1month -.13 - -.01 .05 -.05 .15 .01 .11 
6 months -.02 - .05 .08 -.01 .04 .07 .11 
12 months  -.05 - -.03 .10 -.07 .06 .13 .02 
11β-HSD-1 
 
THF+5aTHF/
THE 
 
1 week -.23t - .04 .17 .25 -.24 .13 -.11 
1 month -.16 -.15 .22 -.25* .16 -.22 -.01 .15 
3 months -.21t - .09 -.03 .06 .29* -.14 -.02 
6 months .06 .02 -.03 .02 .06 -.03 .02 -.18 
12 months -.32* -.16 -.01 -.10 -.10 .18 -.24 -.06 
11β-HSD-2† 
 
F/E 
 
1 week -.35* - -.24 -.22 -.38** .10 -.12 -.08 
1 month .04 -.02 .19 .09 .02 -.03 .30* .28* 
3 months -.06 - .04 .02 -.13 .27* -.22 .25 
6 months .03 .01 -.20 -.03 .07 .05 .17 -.04 
12 months .09 .09 -.20 -.11 -.30* .18 .01 -.04 
5α-reductase 
 
5aTHF/THF 
 
1 week -.29* - -.28* -.41** -.18 .58*** -.23 -.06 
1 month -.31* .12 -.28* -.45** -.29* .27* -.18 -.28* 
3 months -
.45** 
- -.38** -.29* -.24 .50*** -.21 -.22 
6 months -
.40** 
.08 -.29* -.20 -.17 .54*** -.29* -.14 
12 months -
.39** 
.00 -.19 -.28* -.29* .28* -.26 .13 
Total F 
Metabolites 
1 week -.03 - .02 -.05 -.19 .25 -.23 .12 
1 month -.14 -.13 -.06 -.02 .03 .17 .01 -.19 
3 months -.07 - -.20 -.24 -.06 -.12 -.08 -.04 
6 months -.26* -.01 -.26* -.23 -.13 .45** -.25* .09 
12 months .03 .43** -.06 -.18 -.19 .33* -.12 .43** 
*p<.05, **p<.01, ***p<.001 † greater F/E ratios indicate lower 11βHSD-2 activity.   
THF =tetrahydrocortisol, THE =tetrahydrocortisone, E=cortisone, F=cortisol 
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Table 5: 1 Tailed partial correlation coefficients between cortisol metabolism and 
maternal symptoms of depression at 1, 6 and 12 months and ΔBMI. 
t=trend: p<.1; *p<.05; **p<.01 † greater F/E ratios indicate lower 11βHSD-2 activity. 
THF =tetrahydrocortisol, THE =tetrahydrocortisone, E=cortisone, F=cortisol.  
§ Analyses adjusted for demographics and breastfeeding duration. ΔBMI and cortisol 
metabolism analyses adjusted for demographics, breastfeeding duration and 
symptoms of postnatal depression at 12 months. 
 
 Time EPDS
§
 ΔBMI  
1 week to 12 
months§ 
11β-HSD-1 
 
conversion of cortisone 
to cortisol; 
THF+5aTHF/THE 
1 week - -.39* 
1 month -.10 -.20 
3 months - -.17 
6 months .05 .05 
12 months -.14 -.30* 
11β-HSD-2† 
 
conversion of cortisol 
to cortisone; F/E 
1 week - -.36* 
1 month -.09 .01 
3 months - -.05 
6 months .01 .07 
12 months .03 .15 
5α-reductase 
 
clearance of cortisol to 
tetrahydrometabolites; 
5aTHF/THF 
1 week - -.01 
1 month .17 -.18 
3 months - -.33* 
6 months .13 -.25t 
12 months -.01 -.33* 
Total F Metabolites 
 
Total cortisol secretion 
rate;  μg/g urinary 
creatinine 
1 week - .07 
1 month -.16 -.08 
3 months - .10 
6 months -.01 -.01 
12 months .50** .28t 
